The Hardest Number for a Startup Founder to Accept: Their Valuation ft Justin Farry

Every startup founder believes their company is different. They've spent years developing the technology, solving difficult engineering problems, raising capital, building a team, and chasing milestones that often come with enormous personal sacrifice. It's no surprise that many founders become emotionally attached to the value they believe their company deserves.
The challenge is that investors don't value emotion, but risk.

In this episode of MedTech Snapshot, Justin Farry, CFO of Endovascular Engineering, explains that the most defensible startup valuations aren't built on optimism. They're built on evidence.

​Every Milestone Changes the Conversation
One of the biggest misconceptions Justin addresses is that all pre-revenue companies should be valued similarly, which isn't true.

A startup with promising bench testing isn't in the same position as one that has completed first-in-human procedures. Likewise, a company entering a pivotal clinical trial carries a very different level of risk than one generating early commercial revenue.

Every milestone matters because every milestone reduces uncertainty.
As Justin explains: "Every milestone that you achieve fundamentally reduces risk, and the valuation typically goes up."

Investors aren't simply buying technology. They're evaluating how much uncertainty still exists between where a company is today and a successful commercial outcome.

Why Founders Often Overvalue Their Companies
Valuation quickly becomes an emotional discussion. Founders naturally see years of hard work, sleepless nights, and personal investment reflected in their company. Investors, however, are evaluating market opportunity, comparable transactions, financial projections, and execution risk.

Those perspectives don't always align. Justin explains that guiding founders through this process requires more than financial expertise. It requires emotional intelligence.

Rather than telling founders what they want to hear, advisors should help them build objective financial models, forecast realistic revenue, and apply valuation methods that can be defended during fundraising and acquisition discussions.
The goal isn't to lower expectations.
The goal is to replace assumptions with evidence.

Why Comparable Transactions Matter
One of the most important inputs in any valuation is understanding what similar companies have actually sold for. Looking at comparable acquisitions helps founders answer critical questions:

• What stage was the company in?
• Who acquired them?
• What valuation multiple was paid?
• How does my company compare?

This provides context that removes much of the guesswork from negotiations.
After performing this analysis repeatedly for early-stage MedTech companies, Justin and his son built InflectionBI, a platform designed to make acquisition data more accessible to founders, investors, and strategic buyers. Instead of relying on isolated examples or outdated assumptions, companies can benchmark themselves against a broad database of medical device transactions.

Don't Compare Yourself to a Unicorn
One mistake Justin cautions founders against is anchoring their expectations to headline acquisitions. Every industry has companies that achieve extraordinary valuations, but those transactions are exceptions, not the rule.
Basing your expectations on a once-in-a-generation acquisition can create unrealistic expectations that ultimately hurt fundraising discussions.
Instead, Justin recommends focusing on the broader market.
Median transaction values, comparable companies, and objective financial data provide a much stronger foundation than chasing unicorn outcomes.

A Defensible Valuation Builds Credibility
Ultimately, valuation is about finding the number you can defend. When founders understand where their company sits in its development journey, support their projections with realistic financial models, and benchmark against comparable transactions, conversations with investors become far more productive.
Remember, the strongest valuations are built on data.

---

Looking for more support?
If you have questions about this topic or want to explore how our team can help with your MedTech project, contact us here.
Want to see what we do?
Visit our Services page or contact us directly to talk through your project and see if we’re the right fit.